22nd Century Group Stock Forecast & Price Prediction 2026-2027

Algorithmic price targets and analysis for XXII based on fundamentals, valuation multiples, and historical data.

$3.88+1.97%
Bearish

Price Target Summary

Bear Case
$3.43
-11.7% from current
Base Case
$88.55
+2179.3% from current
Bull Case
$159.39
+4002.8% from current

Technical Outlook

52-Week Range Analysis

$3.61$841.80
Current: $3.88
Support Level
$87.43
Resistance Level
$757.98
From 52W High
-99.5%
From 52W Low
+7.6%

Fundamental Analysis

Revenue Growth Projection

Year 1 Projected
$18.1M
Year 2 Projected
$18.1M
Year 3 Projected
$18.1M

Based on +0.0% YoY growth, tapered 20% per year in outer projections.

Valuation vs Peers

Current P/S
0.11x
Sector Median P/S
2.5x
Assessment
Undervalued vs sector

Cash Position

Cash on Hand
N/A
Total Debt
N/A

Key Metrics

Current Price$3.88
Market Cap$2.0M
P/S Ratio0.11x
Revenue (TTM)$18.1M
Revenue Growth (YoY)+0.0%
Gross Margin36.3%
Cash on HandN/A
Total DebtN/A
52W High$841.80
52W Low$3.61

Signal Breakdown

Overall Signal: Bearish
  • Negative or flat revenue growth
  • Below-average gross margins
  • Trading more than 50% below 52-week high
  • P/S ratio below sector median suggests upside

Risk Factors

  • Cannabis remains federally illegal in the United States, creating regulatory uncertainty.
  • The cannabis sector is highly competitive with ongoing price compression in many markets.

Analyst Summary

22nd Century Group (XXII) is a Biotech cannabis company with contracting revenue and a market capitalization of $2.0M. Based on trailing revenue of $18.1M and a P/S ratio of 0.11x, the stock appears undervalued relative to the sector median of 2.5x. Our algorithmic base-case price target of $88.55 implies upside of 2179.3% from current levels. The overall signal is bearish, as several fundamental metrics are under pressure. Investors should weigh the 2 identified risk factors before making any investment decision.

Frequently Asked Questions

What is the price target for XXII?+
Our algorithmic base-case price target for 22nd Century Group (XXII) is $88.55, with a bear case of $3.43 and a bull case of $159.39. These targets are derived from sector-average and premium P/S multiples applied to projected revenue.
Is XXII a buy right now?+
Based on our algorithmic analysis, XXII currently carries a bearish signal. Negative or flat revenue growth. Below-average gross margins. This is not a buy or sell recommendation — always do your own due diligence.
What is the revenue forecast for 22nd Century Group?+
Based on the current year-over-year growth rate of +0.0%, we project XXII revenue at $18.1M in Year 1, $18.1M in Year 2, and $18.1M in Year 3. Growth rates are tapered in outer years.
What are the risks of investing in XXII?+
Cannabis remains federally illegal in the United States, creating regulatory uncertainty. The cannabis sector is highly competitive with ongoing price compression in many markets.
How does XXII valuation compare to the cannabis sector?+
XXII has a trailing P/S ratio of 0.11x compared to the cannabis sector median of 2.5x. The stock undervalued vs sector.

Important Disclaimer

This is not financial advice. Forecasts are algorithmic projections based on historical data and should not be used as the sole basis for investment decisions. Past performance does not guarantee future results. Cannabis stocks carry significant risk including regulatory, market, and operational risks. Always consult with a qualified financial advisor before making investment decisions. Cannabismarketcap does not recommend buying, selling, or holding any security.

← Back to XXII OverviewAll Cannabis Stocks